|
|
Post by mango on Apr 7, 2023 10:58:13 GMT -5
Agree it doesn’t equate to a promise to sell off the division if not CFBE, nor would it be wise to show that card even if it were the case. “Kinda taken the board’s feedback and kinda mandated” kinda gives plenty of wiggle room to be interpreted different ways. Plus, even if the plan is to sell off the division, that can’t be done without a buyer. Agree, and discussing a sale or a buyer is not interesting because of how unlikely it is (at this time). It’s also worth noting that the next comment Mike made with regard to CFBE for the “endocrine” unit was that “Afrezza is already CFBE”. I’m not angry or upset about V-Go, but I do agree with sayhey24 (and awesomo) that it needs to be able to pay for itself, or be discontinued. Afrezza, unfortunately, also cannot be a charity, but I know I would be willing to be operating at a small loss for a few more years, but according to Mike’s comment, that’s not even a concern. Apparently India will not make much money, Mike said international insulin sales are always lower than US (or something to that effect). I believe Peds is going to shift things in a big way. Let’s look at this. Afrezza will be the first time in history a non subq insulin is offered to pediatrics. Kids are injecting 3-5 times a day. Think about the nuances and burden on not just the kids but the parents. There’s fear with the injections, pain, inconvenience, scars, lumps, cutaneous amyloidosis, hypos, etc. Virtually all of that disappears with Afrezza. If we can come out on top with just one of the primary endpoints that will be huge. It’s a noninferiority trial but it appears there is 3 superiority primary endpoints. No idea how that works, but if we can show an improvement in A1C or safety compared to the subq injections that will change the SoC. If we outperform in all the primaries then it’s going to be HUGE stuff. Will make the SoC authors tremble  |
|
|
|
Post by Clement on Apr 7, 2023 12:28:15 GMT -5
wsw.com/webcast/svb8/mnkd/1613790February 15, 2023 1:40 p.m. ET SVB Securities Global Biopharma Conference MC said: "... we have kinda taken the board's feedback and kinda mandated that the diabetes business is gonna track to CFBE by the end of this year." Doesn’t sound anything like what some people have been saying. Based on the two times Mike has mentioned the word mandate that I’m aware of, it appears the Board is wanting CFBE of the diabetes business by end of year and making that a number 1 priority. It does not imply MannKind will be selling off the diabetes business if they fail to reach that goal, and I highly doubt that would ever happen, especially with Peds approval coming next year, India approval, and this new large scale Pump Switch trial. If you listen to Mike in the recent calls he gives absolutely no indication selling off Afrezza, but regardless, it appears they are confident of CFBE by end of year and are “mandating” that happen. I personally believe people have taken what he has said out of context. “Kinda mandate” and “that’s our number one mandate” does not equate to selling off the business if not successful. Yes, I agree. Also, it might have been an admonition from the board that MC does not go big on EBU expenses this year, such as hiring a lot of additional salespeople. (MC mentions in the video that we will eventually need a lot more salespeople in EBU. EBU - Endocrine Business Unit) |
|
|
|
Post by radgray68 on Apr 7, 2023 16:18:08 GMT -5
Happy Friday everyone.
I noticed they went to calling it the EBU a while back. I don't remember if that was before or after V-GO. But the recent company machinations have me asking a question.
Anybody think we may have plans on getting to profitability and then spinning off the EBU? New ticker symbol MANN perhaps?
|
|
|
|
Post by letitride on Apr 7, 2023 17:00:16 GMT -5
I believe theres a guy named Kevin that swears by it.
|
|
|
|
Post by hellodolly on Apr 8, 2023 8:49:10 GMT -5
Happy Friday everyone. I noticed they went to calling it the EBU a while back. I don't remember if that was before or after V-GO. But the recent company machinations have me asking a question. Anybody think we may have plans on getting to profitability and then spinning off the EBU? New ticker symbol MANN perhaps? EBU = Effective Business Unit? |
|
|
|
Post by porkini on Apr 8, 2023 9:48:31 GMT -5
Happy Friday everyone. I noticed they went to calling it the EBU a while back. I don't remember if that was before or after V-GO. But the recent company machinations have me asking a question. Anybody think we may have plans on getting to profitability and then spinning off the EBU? New ticker symbol MANN perhaps? EBU = Effective Business Unit? I think Clement had it a couple posts above - Endocrine Business Unit |
|
|
|
Post by prcgorman2 on Apr 8, 2023 9:53:21 GMT -5
Happy Friday everyone. I noticed they went to calling it the EBU a while back. I don't remember if that was before or after V-GO. But the recent company machinations have me asking a question. Anybody think we may have plans on getting to profitability and then spinning off the EBU? New ticker symbol MANN perhaps? Interesting question. If so, I would not be stunned if Mike chose to be the CEO of the spin-off. If I was in his shoes, I could not possibly be unmoved by the messages and videos of persons with diabetes who share their “life changing” experiences using Afrezza. It never gets old and it never seems to stop. It is easy to believe Afrezza can be commercially successful with a much larger percentage of the prandial (mealtime) market, and difficult to think otherwise. The old saying is, “Build a better mousetrap, and the world will beat a path to your door”. A better saying I remember from one of my business classes is, “The way to create a successful business is to find a problem and solve it”. Al Mann was endlessly innovative and his obsession with improving treatment of diabetes has earned billions of dollars and dramatically improved the lives of countless diabetics. Afrezza solves not just one problem, but multiple. And it does it in a way that is unmatched except by a healthy pancreas as can be seen with a CGM. If you strapped CGMs to a healthy non-diabetic, and a person with diabetes being treated with Afrezza and had them both eat a plate of spaghetti with a nice piece of italian bread, the CGMs would tell the story. The question of a spin-off business unit is interesting, and assuming the spin-off was public, I would probably shift a significant amount of my MNKD investment to it. But, I hope they don’t. I think they’ve built a nice little pipeline company, and EBU makes sense, but there are a lot of questions about how a spin-off would work. Do they lease manufacturing from the non-EBU company? Build a new manufacturing facility (which takes years to build and certify), and who has the patents for TS? If Afrezza were to somehow take off, it might make sense, but I question doing that anytime in the next few years. |
|
|
|
Post by cretin11 on Apr 8, 2023 20:53:09 GMT -5
Kevin’s been calling for the spin-off for many years now. The prediction wasn’t prescient back then, nor is it now.
|
|
|
|
Post by sportsrancho on Apr 9, 2023 11:27:43 GMT -5
Exactly
|
|
|
|
Post by mango on Apr 10, 2023 13:13:13 GMT -5
MannKind apparently is in the planning phase for a tour of the award winning Danbury Manufacturing Facility for retail investors.
I’m not sure if this will coincide with the ASM or not. IR mentioned it to me during our back and forth regarding the VGo operating costs, etc.
I’d recommend those who are interested to go ahead and drop a line to IR expressing interest. I asked ahead if it were ok to pass this info along to shareholder friends.
|
|
|
|
Post by runner on Apr 10, 2023 13:16:13 GMT -5
MannKind apparently is in the planning phase for a tour of the award winning Danbury Manufacturing Facility for retail investors. I’m not sure if this will coincide with the ASM or not. IR mentioned it to me during our back and forth regarding the VGo operating costs, etc. I’d recommend those who are interested to go ahead and drop a line to IR expressing interest. I asked ahead if it were ok to pass this info along to shareholder friends. I, along with some others on this board, toured the Danbury facility in 2015 when the annual shareholder meeting was held there. It was very interesting, I recommend it. |
|
|
|
Post by kc on Apr 17, 2023 11:32:28 GMT -5
Less … acup of coffee…a dozen donuts.. a bunch of bagels .. Poland spring water they already have the hallway and lobby 😀 OH ! I FORGOT… pens and hats … still have mine I still have my pen and hat too. Most expensive bloody pen and hat I ever bought! ME TOO! |
|
|
|
Post by BD on Apr 17, 2023 12:06:49 GMT -5
MannKind apparently is in the planning phase for a tour of the award winning Danbury Manufacturing Facility for retail investors. I’m not sure if this will coincide with the ASM or not. IR mentioned it to me during our back and forth regarding the VGo operating costs, etc. I’d recommend those who are interested to go ahead and drop a line to IR expressing interest. I asked ahead if it were ok to pass this info along to shareholder friends. I, along with some others on this board, toured the Danbury facility in 2015 when the annual shareholder meeting was held there. It was very interesting, I recommend it. I was there! I kept thinking it wouldn't be long until the production capacity of that place wouldn't be enough. Ha. |
|
|
|
Post by lennymnkd on Apr 17, 2023 12:23:40 GMT -5
I was there! I kept thinking it wouldn't be long until the production capacity of that place wouldn't be enough. Ha. Me too .. but I think the time has come . |
|
|
|
Post by prcgorman2 on Apr 17, 2023 13:00:50 GMT -5
I, along with some others on this board, toured the Danbury facility in 2015 when the annual shareholder meeting was held there. It was very interesting, I recommend it. I was there! I kept thinking it wouldn't be long until the production capacity of that place wouldn't be enough. Ha. I remember thinking at that time I hoped they would need to build another facility in a geographically diverse location both for capacity and business continuity. Sounds like MNKD and UTHR are moving that way as well. For sure Mike spent some time talking about adding capacity for Tyvaso DPI, especially if the additional indications are approved. I got the feeling they are having to manage through the demand. A good problem to have although adding capacity is not a trivial exercise or a quick one. |
|
